Role of Glucagon-like Peptide-1 (GLP-1) Agonists in the Management of Diabetic Patients with or without COVID-19

Glucagon-like peptide 1 (GLP-1) is a gut-derived hormone released after a meal, which alleviates hyperglycemia, increases β-cell survival, reduces body weight, and reduces inflammation. These thrilling effects motivated clinical studies to discover the potential use of GLP-1 receptor agonists (GLP-1 RAs) in the management of T2D. GLP-1 RAs are potential anti-diabetic agents that can reduce blood pressure, glucose levels, HbA1c and, weight loss without hypoglycemia risk. This manuscript reviews the importance of GLP-1 RAs‎ and their role in the management of T2D with or without COVID-19 infection. Hence, this manuscript can help physicians and researchers to choose the most appropriate drugs for the individualized treatment of subjects.

[1]  C. Reid,et al.  Experiences With COVID-19 , 2022, Nursing research.

[2]  F. Mirzaei,et al.  Importance of hyperglycemia in COVID-19 intensive-care patients: Mechanism and treatment strategy , 2021, Primary Care Diabetes.

[3]  Majid Rezaei Basiri,et al.  The Importance of Molecular and Clinical Laboratory Tests in Diagnosis and Treatment of Coronavirus Disease , 2021, Journal of Pharmacy and Pharmacology.

[4]  S. Dima,et al.  COVID-19 and diabetes mellitus: Unraveling the hypotheses that worsen the prognosis (Review). , 2020, Experimental and therapeutic medicine.

[5]  A. Scheen.  DPP-4 inhibition and COVID-19: From initial concerns to recent expectations , 2020, Diabetes & Metabolism.

[6]  F. Mirzaei,et al.  Alcohol Misuse May Increase the Severity of COVID-19 Infections , 2020, Disaster Medicine and Public Health Preparedness.

[7]  F. Mirzaei,et al.  Letter to the Editor regarding ‘COVID-19 and diabetes: What does the clinician need to know?’ , 2020, Primary Care Diabetes.

[8]  F. Mirzaei,et al.  Letter from Iran: Experiences with COVID‐19 , 2020, Respirology.

[9]  R. Pop-Busui,et al.  Managing Hyperglycemia in the COVID-19 Inflammatory Storm , 2020, Diabetes.

[10]  F. Strollo,et al.  ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role? , 2020, Diabetes Therapy.

[11]  M. Goodarzi,et al.  Anethum graveolens L‎. Alleviates Sperm ‎Damage by Limiting Oxidative Stress ‎and Insulin ‎Resistance ‎in ‎Diabetic Rats ‎ , 2020 .

[12]  S. Del Prato,et al.  COVID-19 in people with diabetes: understanding the reasons for worse outcomes , 2020, The Lancet Diabetes & Endocrinology.

[13]  M. Rizzo,et al.  Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights , 2020, Journal of cardiovascular pharmacology and therapeutics.

[14]  E. Liberopoulos,et al.  COVID-19 and diabetes: What does the clinician need to know? , 2020, Primary Care Diabetes.

[15]  F. Mirzaei,et al.  Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings , 2020, International Journal of Surgery.

[16]  H. Grill,et al.  Glucagon-like peptide 1 (GLP-1) , 2019, Molecular metabolism.

[17]  P. Schlich,et al.  Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients. , 2019, Diabetes & metabolic syndrome.

[18]  L. B. Knudsen,et al.  The Discovery and Development of Liraglutide and Semaglutide , 2019, Front. Endocrinol..

[19]  F. Mirzaei,et al.  Investigation of protective effects of coenzyme Q10 on impaired synaptic plasticity in a male rat model of Alzheimer’s disease , 2019, Brain Research Bulletin.

[20]  V. Preumont,et al.  Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: A retrospective real-life study in 131 patients. , 2019, Diabetes & metabolic syndrome.

[21]  M. Goodarzi,et al.  Dill-normalized liver lipid accumulation, oxidative stress, and low-density lipoprotein receptor levels in high cholesterol fed hamsters , 2018, ARYA atherosclerosis.

[22]  Ş. Çetinkalp,et al.  Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease. , 2018, Diabetes & metabolic syndrome.

[23]  C. Apovian,et al.  Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon , 2018, Current Obesity Reports.

[24]  K. Adeli,et al.  GLP-1 Elicits an Intrinsic Gut–Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[25]  J. Lovshin.  Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. , 2017, Canadian journal of diabetes.

[26]  E. Hoorn,et al.  GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes , 2017, Nature Reviews Nephrology.

[27]  D. Hinnen.  Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes , 2017, Diabetes Spectrum.

[28]  Young In Park,et al.  Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes. , 2017, American health & drug benefits.

[29]  M. Goodarzi,et al.  Role of resveratrol in the management of insulin resistance and related conditions: Mechanism of action , 2017, Critical reviews in clinical laboratory sciences.

[30]  Dong Yun Lee,et al.  Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes , 2017, Annals of pediatric endocrinology & metabolism.

[31]  Lillian L Smith,et al.  Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist. , 2016, P & T : a peer-reviewed journal for formulary management.

[32]  F. Bäckhed,et al.  Microbial regulation of GLP-1 and L-cell biology , 2016, Molecular metabolism.

[33]  Jennifer M. Trujillo,et al.  Advances in the treatment of type 2 diabetes: impact of dulaglutide , 2016, Diabetes, metabolic syndrome and obesity : targets and therapy.

[34]  Laurentiu M. Pop,et al.  Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. , 2016, The Journal of clinical endocrinology and metabolism.

[35]  V. Tremaroli,et al.  Insulin-like peptide 5 is a microbially regulated peptide that promotes hepatic glucose production , 2016, Molecular metabolism.

[36]  P. Santisteban,et al.  Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats. , 2015, Endocrinology.

[37]  J. Holst,et al.  Liraglutide for Type 2 diabetes and obesity: a 2015 update , 2015, Expert review of cardiovascular therapy.

[38]  G. Lewis,et al.  Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism , 2015, Diabetes.

[39]  K. Adeli,et al.  Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain–Gut Axis , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[40]  M. Nieuwdorp,et al.  GLP1, an Important Regulator of Intestinal Lipid Metabolism. , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[41]  T. Hansen,et al.  GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study , 2015, Diabetes.

[42]  Jung-Mo Ahn,et al.  Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications , 2014, Journal of medicinal chemistry.

[43]  C. Lamendola,et al.  Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[44]  R. Reinhardt,et al.  Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist , 2014, Postgraduate medicine.

[45]  Z. Pausova,et al.  GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance , 2014, Molecular metabolism.

[46]  K. Adeli,et al.  Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states. , 2014, Cardiovascular & hematological disorders drug targets.

[47]  B. Ahrén,et al.  Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors , 2014, Diabetes.

[48]  P. Craddy,et al.  Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison , 2014, Diabetes Therapy.

[49]  S. Madsbad.  The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications , 2014, Diabetes, obesity & metabolism.

[50]  A. Mohammadi,et al.  Effect of garlic extract on some serum biochemical parameters and expression of npc1l1, abca1, abcg5 and abcg8 genes in the intestine of hypercholesterolemic mice. , 2013, Indian journal of biochemistry & biophysics.

[51]  F. Bäckhed,et al.  Microbial modulation of energy availability in the colon regulates intestinal transit. , 2013, Cell host & microbe.

[52]  Zhijun Wang,et al.  Treating Type 2 Diabetes Mellitus with Traditional Chinese and Indian Medicinal Herbs , 2013, Evidence-based complementary and alternative medicine : eCAM.

[53]  H. Vaudry,et al.  Structural and Molecular Conservation of Glucagon-Like Peptide-1 and Its Receptor Confers Selective Ligand-Receptor Interaction , 2012, Front. Endocrin..

[54]  Mahmoodi Mehdi,et al.  Hepatoprotective effects of hydroalcoholic extract of Allium hirtifolium (Persian shallot) in diabetic rats , 2012, Journal of basic and clinical physiology and pharmacology.

[55]  G. Lewis,et al.  Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[56]  D. Donnelly,et al.  The structure and function of the glucagon‐like peptide‐1 receptor and its ligands , 2012, British journal of pharmacology.

[57]  K. Adeli,et al.  Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states , 2012, Current opinion in lipidology.

[58]  A. Garber.  Long-Acting Glucagon-Like Peptide 1 Receptor Agonists , 2011, Diabetes Care.

[59]  L. Szablewski.  Glucose and Lipid Metabolism , 2011 .

[60]  S. Weisnagel,et al.  Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes , 2011, Diabetes, obesity & metabolism.

[61]  A. Herling,et al.  Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes , 2010, Regulatory Peptides.

[62]  R. Kushner,et al.  Emerging role of GLP-1 receptor agonists in the treatment of obesity , 2010, Diabetes, metabolic syndrome and obesity : targets and therapy.

[63]  D. Drucker,et al.  The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice , 2010, Diabetologia.

[64]  W. Langhans,et al.  Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. , 2009, Endocrinology.

[65]  R. DeFronzo,et al.  Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. , 2008, American journal of physiology. Endocrinology and metabolism.

[66]  K. Parhofer.  [Glucagon-like peptide 1 (GLP-1)]. , 2007, MMW Fortschritte der Medizin.

[67]  B. Estour,et al.  Constitutional thinness and lean anorexia nervosa display opposite concentrations of peptide YY, glucagon-like peptide 1, ghrelin, and leptin. , 2007, The American journal of clinical nutrition.

[68]  J. Egan,et al.  Mechanisms of action of glucagon-like peptide 1 in the pancreas. , 2007, Pharmacology & therapeutics.

[69]  Michael B Wheeler,et al.  The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. , 2002, Diabetes.

[70]  J. Holst,et al.  Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients , 2002, Diabetologia.

[71]  P. Tso,et al.  Intestinal Lipid Metabolism , 2012, Springer US.

[72]  C. Kahn,et al.  Insulin signalling and the regulation of glucose and lipid metabolism , 2001, Nature.

[73]  P. Damsbo,et al.  Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. , 2001, Diabetes care.

[74]  S. Raptis,et al.  Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[75]  J. Holst.  Gut hormones as pharmaceuticals From enteroglucagon to GLP-1 and GLP-2 , 2000, Regulatory Peptides.

[76]  J. Holst,et al.  Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. , 1999, Diabetes care.

[77]  S. Bloom,et al.  Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. , 1999, Endocrinology.

[78]  S. Bloom,et al.  Repeated Intracerebroventricular Administration of Glucagon-Like Peptide-1-(7-36) Amide or Exendin-(9-39) Alters Body Weight in the Rat* *This work was supported by the United Kingdom Medical Research Council. , 1999, Endocrinology.

[79]  J. Rehfeld,et al.  The new biology of gastrointestinal hormones. , 1998, Physiological reviews.

[80]  JD Ward,et al.  Standards of medical care in UK , 1997, The Lancet.

[81]  J. Levy,et al.  Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM , 1997, Diabetologia.

[82]  A. Hamsten,et al.  The Antidiabetogenic Effect of GLP-1 Is Maintained During a 7-Day Treatment Period and Improves Diabetic Dyslipoproteinemia in NIDDM Patients , 1996, Diabetes Care.